48 related articles for article (PubMed ID: 38720626)
1. Comparison of outcomes between early-stage cervical cancer patients without high-risk factors undergoing adjuvant concurrent chemoradiotherapy and radiotherapy alone after radical surgery.
Zhou Y; Wang W; Tang J; Hu K; Zhang F
BMC Cancer; 2024 Apr; 24(1):548. PubMed ID: 38689248
[TBL] [Abstract][Full Text] [Related]
2. Nomogram for Predicting Survival in Locally Advanced Cervical Cancer with Concurrent Chemoradiotherapy plus or Not Adjuvant Chemotherapy: A Retrospective Analysis Based on 2018 FIGO Staging.
Hua L; Wei M; Feng C; Li S; Wen X; Chen S
Cancer Biother Radiopharm; 2024 Jun; ():. PubMed ID: 38828494
[No Abstract] [Full Text] [Related]
3. Can surgery boost the survival benefit of chemoradiotherapy in T1b1-T2a1 stage cervical cancer with lymph node metastasis? A population-based study.
Wang Y; Lyu Y; Che X; Li J; Feng W
J Gynecol Oncol; 2024 May; 35(3):e36. PubMed ID: 38216135
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors for Nodal Failure in Patients with FIGO IIIC Cervical Cancer Receiving Definitive Image-Guided Radiotherapy.
Liu X; Hou X; Hu K; Zhang F; Wang W; Ren K
Curr Oncol; 2023 Dec; 30(12):10385-10395. PubMed ID: 38132390
[TBL] [Abstract][Full Text] [Related]
5. Peroxiredoxin 2 as a potential prognostic biomarker associated with angiogenesis in cervical squamous cell cancer.
Zhao K; Zhao T; Yang R; Liu J; Hu M
Oncol Lett; 2024 Jul; 28(1):328. PubMed ID: 38807674
[TBL] [Abstract][Full Text] [Related]
6. Effect of different treatment modalities on the prognosis of patients with stage IIIC cervical cancer.
Su X; Huang J; Wang N
Front Oncol; 2024; 14():1405778. PubMed ID: 38863632
[TBL] [Abstract][Full Text] [Related]
7. Do Cervical Cancer Patients Diagnosed with Opportunistic Screening Live Longer? An Arkhangelsk Cancer Registry Study.
Roik EE; Nieboer E; Kharkova OA; Grjibovski AM; Postoev VA; Odland JØ
Int J Environ Res Public Health; 2017 Nov; 14(12):. PubMed ID: 29186874
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in uterine adenosarcoma: subanalysis of the SARCUT study.
Mancari R; Yusuf Y; Macuks R; Achimas-Cadariu P; Piek JM; Sperduti I; Corrado G; Vizza E; Zapardiel I
Front Oncol; 2024; 14():1393707. PubMed ID: 38835369
[TBL] [Abstract][Full Text] [Related]
9. Level of Concordance of Pre-, Intra-, and Postoperative Staging in Cervical Cancers (TREYA Study).
Toure M; Bambara AT; Kouassi KKY; Seka EN; Dia JM; Yao I; Kimso O; Adoubi I
J Oncol; 2017; 2017():8201462. PubMed ID: 29081801
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes and Prognostic Factors in Stage III C Cervical Cancer Patients Treated with Radical Radiotherapy or Radiochemotherapy.
Zhang W; Yu H; Xiu Y; Meng F; Wang Z; Zhao K; Wang Y; Chen Z; Liu J; Chen J; Sun B
Technol Cancer Res Treat; 2024; 23():15330338241254075. PubMed ID: 38720626
[No Abstract] [Full Text] [Related]
11. Rationality of FIGO 2018 IIIC restaging of cervical cancer according to local tumor size: A cohort study.
Duan H; Li H; Kang S; Zhao H; Chen B; Wang L; Li P; Wang Y; Wang W; Lang J; Liu P; Chen C
Acta Obstet Gynecol Scand; 2023 Aug; 102(8):1045-1052. PubMed ID: 37338046
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of the presence of pelvic and/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC).
van Kol KGG; Ebisch RMF; van der Aa M; Wenzel HB; Piek JMJ; Bekkers RLM
Gynecol Oncol; 2023 Apr; 171():9-14. PubMed ID: 36804623
[TBL] [Abstract][Full Text] [Related]
13. Validation of the 2018 FIGO Staging System for Predicting the Prognosis of Patients With Stage IIIC Cervical Cancer.
Long X; He M; Yang L; Zou D; Wang D; Chen Y; Zhou Q
Clin Med Insights Oncol; 2023; 17():11795549221146652. PubMed ID: 36726607
[TBL] [Abstract][Full Text] [Related]
14. The impact of para-aortic lymph node irradiation on disease-free survival in patients with cervical cancer: A systematic review and meta-analysis.
Bukkems LJH; Jürgenliemk-Schulz IM; van der Leij F; Peters M; Gerestein CG; Zweemer RP; van Rossum PSN
Clin Transl Radiat Oncol; 2022 Jul; 35():97-103. PubMed ID: 35669003
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the 2018 FIGO staging system for cervical cancer.
Mohamud A; Høgdall C; Schnack T
Gynecol Oncol; 2022 Jun; 165(3):506-513. PubMed ID: 35346512
[TBL] [Abstract][Full Text] [Related]
16. Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review.
Qin F; Pang H; Yu T; Luo Y; Dong Y
Technol Cancer Res Treat; 2022; 21():15330338221086403. PubMed ID: 35341413
[TBL] [Abstract][Full Text] [Related]
17. Comparison of survival outcomes between squamous cell carcinoma and adenocarcinoma/adenosquamous carcinoma of the cervix after radical radiotherapy and chemotherapy.
Liu P; Ji M; Kong Y; Huo Z; Lv Q; Xie Q; Wang D; Chen B; Wang H; Cui Z; Wang Q; Bin X; Lang J; Chen C
BMC Cancer; 2022 Mar; 22(1):326. PubMed ID: 35337279
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in locally advanced cervical cancer with pelvic lymph node metastasis.
Pinto PJJ; Chen MJ; Santos Neto E; Faloppa CC; De Brot L; Guimaraes APG; da Costa AABA; Baiocchi G
Int J Gynecol Cancer; 2022 Mar; 32(3):239-245. PubMed ID: 35256409
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
